PKCW PTY LTD and Australian Community Pharmacy Authority

Link copied
Case Copied 14 min read

PKCW PTY LTD and Australian Community Pharmacy Authority [2024] AATA 184 (5 February 2024)

Division:GENERAL DIVISION

File Number(s):      2023/2004

Re:PKCW PTY LTD

APPLICANT

AndAustralian Community Pharmacy Authority

RESPONDENT

DECISION

Tribunal:Senior Member A Poljak

Date:5 February 2024

Place:Sydney

The decision under review is set aside and substituted with a decision to recommend the applicant’s application.

...........................[SGD].............................................

Senior Member A Poljak

Catchwords

HEALTH – Pharmacists – retail pharmacy – Application for approval to supply pharmaceutical benefits at premises other than premises in respect of which approval already granted – Where lease was terminated – Item 312(b)(v) – National Health (Australian Community Pharmacy Authority Rules) Determination 2018 (Cth) – Whether exceptional circumstances exist – Decision under review set aside and substituted.

Legislation
National Health Act 1953 (Cth)

National Health (Australian Community Pharmacy Authority Rules) Determination 2018 (Cth)

Cases

BVZ16 v Minister for Immigration and Border Protection [2017] FCA 958
Clare v Australian Community Pharmacy Authority [2015] FCA 653

Clyne v. Deputy Commissioner of Taxation [1981] HCA 40; (1981) 150 CLR 1, (1981) 35 ALR 567

Secondary Materials

Explanatory Statement issued by authority of the Minister for Healthwhich accompanied the amendments in the National Health (Australian Community Pharmacy Authority Rules) Determination 2018 (Cth)

REASONS FOR DECISION

Senior Member A Poljak

5 February 2024

  1. On 9 February 2023, the applicant, PKCW Pty Ltd, applied for the relocation of an existing PBS approval from the premises at Shops 2-8, 189 Toorak Road South Yarra VIC (the Existing Premises) to premises at 235 Toorak Road, South Yarra VIC (Proposed Premises).

  2. The applicant seeks review of a decision by the Australian Community Pharmacy Authority (Authority) made on 23 March 2023. In that decision, the Authority recommended to the Secretary of the Department of Health and Aged Care (Secretary) that an application to supply pharmaceutical benefits at premises located at the Proposed Premises not be approved under section 90 of the National Health Act 1953 (Cth) (Act).

  3. The Authority considered that the applicant’s application did not meet the requirements set out in rule 10(3)(e) and Item 312(a) and (b) of Schedule 2 of Part 1 of the National Health (Australian Community Pharmacy Authority Rules) Determination 2018 (Cth) (Rules).

    Facts

  4. On 27 July 2020, CW Leasing Services Pty Ltd (CW Leasing) commenced a lease of the Existing Premises.

  5. At the time, the applicant commenced a licence agreement with CW Leasing for use of the Existing Premises as a retail pharmacy and was approved to supply pharmaceutical benefits at the Existing Premises.

  6. From 27 July 2020, the applicant began operating a pharmacy business from the Existing Premises, including the supply of pharmaceutical benefits.

  7. The applicant received its PBS approval in relation to 210 Swan Street Richmond on 29 March 2022. 

  8. On 28 April 2022, the applicant was approved by the Secretary (subsequent to recommendation from the respondent) to relocate its PBS approval from the Existing Premises to premises known as 372…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read PKCW PTY LTD and Australian Community Pharmacy Authority and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] AATA 184
Decision Date

CaseChat Overview and Summary

PKCW Pty Ltd (the applicant) sought judicial review of a decision by the Australian Community Pharmacy Authority (the Authority) concerning its application for approval to supply pharmaceutical benefits at new premises. The dispute arose because the applicant's lease at its existing premises was terminated due to the site's purchase and redevelopment, preventing the supply of pharmaceutical benefits at those premises. The matter was heard by A Poljak SM.

The primary legal issue before the court was whether the circumstances surrounding the applicant's inability to supply pharmaceutical benefits at its existing premises constituted "exceptional circumstances" for the purposes of Item 312(b)(v) of the National Health (Australian Community Pharmacy Authority Rules) Determination 2018 (Cth). This provision allows for relocation if pharmaceutical benefits are unable to be supplied at the existing premises due to a disaster or exceptional circumstances, and will not be able to be supplied there in the future, provided the application is not of a specific kind mentioned elsewhere.

The court reasoned that the term "exceptional circumstances" should be given its ordinary meaning, and the focus must be on whether the *inability to supply* pharmaceutical benefits is the result of such circumstances. Drawing on the Explanatory Statement to the Rules and previous case law, the court noted the intention of Item 312 is to maintain the stability of the pharmacy network while allowing some flexibility. The court found that the unexpected purchase and redevelopment of the site, leading to the early termination of the lease, were rare events not routinely encountered by businesses of this nature. Therefore, these circumstances were deemed to establish exceptional circumstances.

The court set aside the Authority's decision and substituted it with a decision to recommend the applicant's application for approval at the new premises.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Having regard to the available relevant evidence, I am convinced that the circumstances leading to the applicant’s inability to supply pharmaceutical benefits, namely, the unexpected purchase and redevelopment of the site of the Existing Premises and the subsequent early termination of its lease, are rare, and cannot be said to be regularly, or routinely, or normally encountered events for businesses of this nature. Exceptional circumstances are established in the circumstances of this case. Decision The decision under review is set aside and substituted with a decision to recommend the applicant’s application.

Ratio Decidendi

Legal Principle Established

It is not in dispute that the applicant’s application does not meet the requirements of Item 312(a), Item 312(b)(i)-(iv), or Item 312(b)(vi)-(vii). Instead, the applicant relies only upon the exemption in Item 312(b)(v), which is in the following terms: (v)because of a disaster or exceptional circumstances pharmaceutical benefits are unable to be supplied at the existing premises, and will not be able to be supplied at the existing premises in the future, and the application is not of the kind mentioned in item 125 of Part 1 of Schedule 1…Consideration By the time of the scheduled hearing before the Tribunal on 9 October 2023, it was the case that “pharmaceutical benefits are unable to be supplied at the existing premises and will not be able to be supplied at the Existing Premises in the future”. The Authority accepts that the applicant’s application is not of the kind mentioned in Item 125 of Part 1 of Schedule 1 of the rules. The applicant contends that the early termination of the lease of the Existing Premises, as a result of the purchase and redevelopment of the site, are circumstances which constitute “exceptional circumstances” for the purposes of Item 312(b)(v) of the Rules. The applicant further contends that the proposed relocation is a move of approximately 109 metres along the street and will have no effect on other pharmacies. If the relocation is not permitted, the existing pharmacy will be forced to cease to exist, affecting the stability of the network serving the local area. The term “exceptional circumstances” is not defined in the Rules and should be given its ordinary meaning. I do not accept that the test is merely whether circumstances affecting an applicant are exceptional in the general sense. The question is whether the inability to supply pharmaceutical benefits is the result of exceptional circumstances. The Explanatory Statement to the Rules provides some guidance to its interpretation. That Explanatory Statement sets out that Item 312: “…aims to ensure the distribution and stability of the network of approved pharmacies is not adversely affected by the relocation of existing approvals, whilst allowing some flexibility for relocations within the local area… an approval cannot be relocated more than once every 5 years, except in specified circumstances. The intention of this provision is to prevent the establishment of a temporary/demountable pharmacy which is subsequently relocated, where there is no intention of servicing the community at the temporary location long term… The provision relating to disaster or exceptional circumstance, under paragraph 312(b)(v), is not intended to be an alternative to section 91A of the Act, but rather is intended to be for situations where the relocation is long term (i.e. not temporary), as a result of the disaster.”. This is consistent with the objective of maintaining the stability of the scheme for the distribution of pharmaceutical benefits. In Clare v Australian Community Pharmacy Authority [2015] FCA 653 at [55], Reeves J considered the purpose of restricting relocation of premises to which an approval relates:Having created this broad network of pharmacies providing convenient community access to those dispensing pharmacies operating under the PBS, it was obviously important for the integrity of the scheme to ensure that the distribution and stability of that network would not be adversely affected by the relocation of pharmacy premises once they became approved premises under the scheme. It is therefore unsurprising to find limitations placed upon the circumstances in which any approved pharmacy premises may be relocated from the originally approved locations. That is what the requirements in Part 1 of Schedule 1 and the additional requirements in Part 1 of Schedule 3 of the 2011 Rules are directed to.